What is Arcus Biosciences's backlog?

Arcus Biosciences reported $256M of remaining performance obligations at 31 Dec 2025, down 51% from a year earlier and flat from the previous quarter. That is 1.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

How fast does Arcus Biosciences's backlog turn into revenue?

Over the last twelve months Arcus Biosciences recognised revenue equal to about 47% of the backlog it started each quarter with.

Arcus Biosciences (RCUS) backlog: remaining performance obligations

How much revenue Arcus Biosciences already has under contract, how fast it converts, and who it is with.

Data as of 7 Nov 2026.

Open the interactive Backlog view Arcus Biosciences competitor analysis

Arcus Biosciences reported $256M of remaining performance obligations at 31 Dec 2025, down 51% from a year earlier and flat from the previous quarter. That is 1.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.
Net new backlog added in the latest quarter: $0.
Over the last twelve months it turned about 47% of its opening backlog into revenue (12-month conversion).
Customer prepayments (contract liabilities) cover 30.5% of the backlog.
Twelve-month book-to-bill: -0.08, i.e. -0.08 of new orders for every 1 of revenue recognised.
Backlog growth minus revenue growth: -47 points — revenue is catching up with orders.
The latest filed figure is more than 200 days old.

Arcus Biosciences backlog history

Remaining performance obligations at each quarter end (bars) against trailing twelve-month revenue (line).

Amounts in USD. Source: SEC XBRL filings.
Quarter end	Backlog (RPO)	TTM revenue	Coverage	Customer prepayments
31 Dec 2025	$256M	$247M	1.0 yrs	$78.0M
30 Sep 2025	$256M	n/a	n/a	$105M
30 Jun 2025	$256M	n/a	n/a	$131M
31 Dec 2024	$522M	$258M	2.0 yrs	$319M

Questions

What is Arcus Biosciences's backlog?: Arcus Biosciences reported $256M of remaining performance obligations at 31 Dec 2025, down 51% from a year earlier and flat from the previous quarter. That is 1.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.
How fast does Arcus Biosciences's backlog turn into revenue?: Over the last twelve months Arcus Biosciences recognised revenue equal to about 47% of the backlog it started each quarter with.

About these numbers

Remaining performance obligations (RPO) are revenue a company has contracted but not yet recognised, as reported in its SEC filings (XBRL tag RevenueRemainingPerformanceObligation). Coverage = backlog ÷ trailing twelve-month revenue. Book-to-bill = (change in backlog + revenue) ÷ revenue. Conversion = revenue recognised ÷ the backlog at the start of each quarter, summed over four quarters. Counterparty values come from company filings and releases.